Physician profile
Steven B Thom
NPI 1063434637
$2,708.98
in general payments reported to CMS, 2019-2025
27 companies · $567 in 2025
The $567 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $205 · 2021: $475 · 2022: $575 · 2023: $171 · 2024: $249 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $475.60 | 2019-2025 | Clareon Panoptix Pro, Clareon, Dailies Total1 |
| Allergan, INC. | $269.04 | 2020-2021 | |
| Glaukos Corporation | $217.97 | 2022-2025 | Idosetr, Istent Infinite |
| Mallinckrodt Hospital Products INC. | $196.55 | 2020-2024 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $159.68 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| Aerie Pharmaceuticals, INC. | $145.91 | 2019-2020 | |
| The Cameron-Ehlen Group, INC. | $143.82 | 2019-2022 | |
| Abbvie INC. | $127.47 | 2021-2024 | Lumigan, Alphagan P |
| Mallinckrodt Enterprises LLC | $120.33 | 2019 | |
| Medtronic, INC. | $117.52 | 2025 | Micra |
| Oyster Point Pharma, INC. | $116.04 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $94.90 | 2019-2025 | |
| Dompe US, INC. | $86.76 | 2021-2022 | |
| Rxsight INC | $77.19 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Genentech USA, INC. | $64.74 | 2023-2025 | Vabysmo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $55.74 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $50.72 | 2019-2021 | |
| Travere Therapeutics, INC. | $25.64 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $25.00 | 2024 | Zilretta, Iovera, Exparel |
| Bausch & Lomb Americas INC. | $23.84 | 2022 | |
| Apellis Pharmaceuticals, INC. | $21.34 | 2023 | Syfovre |
| Heron Therapeutics, INC. | $18.54 | 2024 | Zynrelef |
| Shire North American Group INC | $17.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.46 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $15.63 | 2022 | |
| Omeros Corporation | $13.55 | 2020 | |
| Horizon Therapeutics Plc | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Thom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.